1. Home
  2. ORGN vs ADAG Comparison

ORGN vs ADAG Comparison

Compare ORGN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Materials Inc.

ORGN

Origin Materials Inc.

N/A

Current Price

$1.12

Market Cap

7.5M

Sector

Industrials

ML Signal

N/A

Logo Adagene Inc.

ADAG

Adagene Inc.

N/A

Current Price

$3.60

Market Cap

254.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ORGN
ADAG
Founded
2008
2011
Country
United States
China
Employees
91
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
254.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ORGN
ADAG
Price
$1.12
$3.60
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.25
AVG Volume (30 Days)
140.7K
186.8K
Earning Date
05-14-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$503.74
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$1.44
52 Week High
$4.11
$4.75

Technical Indicators

Market Signals
Indicator
ORGN
ADAG
Relative Strength Index (RSI) 31.96 52.01
Support Level $0.15 $3.29
Resistance Level $2.33 $4.09
Average True Range (ATR) 0.09 0.31
MACD -0.01 0.00
Stochastic Oscillator 13.00 43.33

Price Performance

Historical Comparison
ORGN
ADAG

About ORGN Origin Materials Inc.

Origin Materials Inc is a technology company with a mission to enable the world's transition to sustainable materials. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include PET circular caps and closures, Para-xylene, carbon black, Levulinic acid, among others, by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: